Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways

Ioannis Morianos, Aikaterini I. Trochoutsou, Gina Papadopoulou, Maria Semitekolou, Aggelos Banos, Dimitris Konstantopoulos, Antigoni Manousopoulou, Maria Kapasa, Ping Wei, Brett Lomenick, Elise Belaidi, Themis Kalamatas, Klinta Karageorgiou, Triantafyllos Doskas, Federica Sallusto, Fan Pan, Spiros D. Garbis, Francisco J. Quintanan, Georgina Xanthou

Research output: Contribution to journalArticle

Abstract

In multiple sclerosis (MS), Th17 cells are critical drivers of autoimmune central nervous system (CNS) inflammation and demyelination. Th17 cells exhibit functional heterogeneity fostering both pathogenic and nonpathogenic, tissue-protective functions. Still, the factors that control Th17 pathogenicity remain incompletely defined. Here, using experimental autoimmune encephalomyelitis, an established mouse MS model, we report that therapeutic administration of activin-A ameliorates disease severity and alleviates CNS immunopathology and demyelination, associated with decreased activation of Th17 cells. In fact, activin-A signaling through activin-like kinase-4 receptor represses pathogenic transcriptional programs in Th17-polarized cells, while it enhances antiinflammatory gene modules. Whole-genome profiling and in vivo functional studies revealed that activation of the ATP-depleting CD39 and CD73 ectonucleotidases is essential for activin-A-induced suppression of the pathogenic signature and the encephalitogenic functions of Th17 cells. Mechanistically, the aryl hydrocarbon receptor, along with STAT3 and c-Maf, are recruited to promoter elements on Entpd1 and Nt5e (encoding CD39 and CD73, respectively) and other antiinflammatory genes, and control their expression in Th17 cells in response to activin-A. Notably, we show that activin-A negatively regulates the metabolic sensor, hypoxia-inducible factor-1α, and key inflammatory proteins linked to pathogenic Th17 cell states. Of translational relevance, we demonstrate that activin-A is induced in the CNS of individuals with MS and restrains human Th17 cell responses. These findings uncover activin-A as a critical controller of Th17 cell pathogenicity that can be targeted for the suppression of autoimmune CNS inflammation.

Original languageEnglish (US)
JournalProceedings of the National Academy of Sciences of the United States of America
Volume117
Issue number22
DOIs
StatePublished - Jun 2 2020

Keywords

  • Activin-A
  • Autoimmune neuroinflammation
  • Cytokines
  • Ectonucleotidases
  • Th17 cell differentiation

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways'. Together they form a unique fingerprint.

  • Cite this

    Morianos, I., Trochoutsou, A. I., Papadopoulou, G., Semitekolou, M., Banos, A., Konstantopoulos, D., Manousopoulou, A., Kapasa, M., Wei, P., Lomenick, B., Belaidi, E., Kalamatas, T., Karageorgiou, K., Doskas, T., Sallusto, F., Pan, F., Garbis, S. D., Quintanan, F. J., & Xanthou, G. (2020). Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 117(22). https://doi.org/10.1073/pnas.1918196117